CLAIMS

1. Use of a protein or polypeptide comprising a polypeptide having at least 75% sequence identity with the amino acid sequence SEQ ID NO: 1 the manufacture of a medicament for the prevention and/or the treatment of brain inflammation occurring or susceptible to occur after brain hemorrhage in a subject in need thereof,

wherein said protein or polypeptide is for administration within 120 hours after the onset of brain hemorrhage.

2. The use according to claim 1, wherein said medicament is for administration within 96 hours after the onset of brain hemorrhage.

3. The use according to claim 1, wherein said medicament is for administration within 72 hours after the onset of brain hemorrhage.

4. The use according to claim 1, wherein said medicament is for administration within 48 hours after the onset of brain hemorrhage.

5. The use according to claim 1, wherein said medicament is for administration within 24 hours after the onset of brain hemorrhage.

6. The use according to any one of claims **1** to **5**, wherein said protein or polypeptide comprises a polypeptide having the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2.

7. The use according to any one of claims **1** to **5**, wherein said protein or polypeptide comprises a polypeptide having the amino acid sequence SEQ ID NO: 2.

8. The use according to any one of claims **1** to **7**, wherein said brain hemorrhage is an intracerebral hemorrhage.

9. The use according to any one of claims **1** to **8**, wherein said medicament is for administration at a dose of about 200 mg to about 20,000 mg per adult per day.

10. Use of a protein or polypeptide comprising a polypeptide having at least 75% sequence identity with the amino acid sequence SEQ ID NO: 1 for the manufacture of a medicament for the prevention and/or the treatment of brain inflammation, wherein said protein or polypeptide is administered within about 120 hours after the onset of brain inflammation.

11. The use according to claim **10**, wherein said medicament is for administration within about 96 hours after the onset of brain inflammation.

12. The use according to claim **10**, wherein said medicament is for administration within about 72 hours after the onset of brain inflammation.

13. The use according to claim **10**, wherein said medicament is for administration within about 15 hours after the onset of brain inflammation.

14. The use according to claim **10**, wherein said medicament is for administration within about 12 hours after the onset of brain inflammation.

15. The use according to claim **10**, wherein said brain inflammation occurs or is susceptible to occur after brain injury and said medicament is for administration within about 120 hours after the onset of brain injury.

16. The use according to claim 15, wherein said medicament is for administration within about 96 hours after the onset of brain injury.

17. The use according to claim 15, wherein said medicament is for administration within about 72 hours after the onset of brain injury.

18. The use according to claim 15, wherein medicament is for administration within about 15 hours after the onset of brain injury.

19. The use according to claim 15, wherein medicament is for administration within about 12 hours after the onset of brain injury.

20. The use according to any one of claims **1** to **19**, wherein said medicament is for administration continuously.

21. The use according to any one of claims **1** to **20**, wherein the polypeptide or protein is comprised in a pharmaceutical composition, and wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.

22. The use according to claim **21**, wherein the pharmaceutical composition further comprises another therapeutic agent.

23. The use according to any one of claims **1** to **20**, wherein the polypeptide or protein is comprised in a kit.